DreamCIS, Inc.
Financials
Valuation Metrics
DreamCIS, Inc.'s Market Cap is ₩802B. At end of 2025 it was ₩1570B. Ranked #1386 of 2,436 in KR market (top 57%), #778 of 1,649 on KOSDAQ (top 47%), #153 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 65%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 80.20B KRW | KR#1,386/2,436 Sec#153/234 |
| Revenue | 69.87B KRW | KR#1,616/2,436 Sec#105/234 |
| Net Income | 6.28B KRW | KR#1,054/2,436 Sec#69/234 |
| Total Assets | 162.93B KRW | KR#1,411/2,436 Sec#112/234 |
| Net Assets | 88.18B KRW | KR#1,476/2,436 Sec#123/234 |
| Employees | 358 | KR#674/2,436 Sec#59/234 |
| Value | ||
| P/E | 12.76x | KR#868/2,436 Sec#52/234 |
| P/B | 0.91x | KR#1,402/2,436 Sec#89/234 |
| P/S | 1.15x | KR#1,490/2,436 Sec#87/234 |
| EV/EBITDA | 15.46x | KR#879/2,436 Sec#50/234 |
| FCF Yield | 16.88% | KR#402/2,436 Sec#8/234 |
| Profitability | ||
| ROE | 7.13% | KR#776/2,436 Sec#55/234 |
| ROA | 3.86% | KR#816/2,436 Sec#72/234 |
| Op. Margin | 6.37% | KR#761/2,436 Sec#64/234 |
| Revenue Growth | 22.87% | KR#590/2,436 Sec#57/234 |
| Earnings Growth | -126.68% | KR#1,422/2,436 Sec#92/234 |
| Financial Health | ||
| Debt Ratio | 184.77% | KR#1,578/2,436 Sec#180/234 |
| Total Debt | 14.84B KRW | KR#1,480/2,436 Sec#129/234 |
| FCF | 13.54B KRW | KR#621/2,436 Sec#35/234 |
| Cash | 26.24B KRW | KR#1,078/2,436 Sec#73/234 |
| Current Ratio | 1.07x | KR#1,745/2,436 Sec#178/234 |
| Net Debt/EBITDA | -2.56x | KR#248/2,436 Sec#13/234 |
| Performance | ||
| 1Y Return | 1.72% | KR#679/2,436 Sec#50/234 |
| 1M Return | -3.41% | KR#1,249/2,436 Sec#126/234 |
| From 52W High | -62.27% | KR#1,826/2,436 Sec#152/234 |
| 1Y MDD | -68.14% | KR#1,867/2,436 Sec#159/234 |
| Trading | ||
| Volume | 160,788 shares | KR#682/2,436 Sec#66/234 |
| Foreign Own. | 50.58% | KR#32/2,436 Sec#2/234 |
| Per Share | ||
| EPS | 257 KRW | KR#1,140/2,436 Sec#79/234 |
| BPS | 3,206 KRW | KR#1,773/2,436 Sec#135/234 |
Company Info
Dream CIS, a Clinical Research Organization (CRO) established in 2000, saw China's top CRO, Tigermed, acquire a stake in 2015. The company provides full-range services including clinical trial design, consulting, and monitoring, as well as comprehensive specialized services such as drug clinical trials, post-market surveillance, and statistical analysis. Leveraging Tigermed's global network, Dream CIS establishes a foundation for multinational clinical trial orders and secures competitiveness through the integration of standard operating procedures. Dream CIS was established in 2000 and is headquartered in Jongno-gu, Seoul.